SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-043563
Filing Date
2023-08-21
Accepted
2023-08-21 08:33:32
Documents
13
Period of Report
2023-08-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K impl-20230821.htm   iXBRL 8-K 89386
2 EX-10.1 impl-ex10_1.htm EX-10.1 4066661
  Complete submission text file 0000950170-23-043563.txt   4617093

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT impl-20230821.xsd EX-101.SCH 2459
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT impl-20230821_lab.xml EX-101.LAB 18778
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT impl-20230821_pre.xml EX-101.PRE 12037
7 EXTRACTED XBRL INSTANCE DOCUMENT impl-20230821_htm.xml XML 5129
Mailing Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119 206-568-1466
IMPEL PHARMACEUTICALS INC (Filer) CIK: 0001445499 (see all company filings)

IRS No.: 263058238 | State of Incorp.: DE | Fiscal Year End: 0426
Type: 8-K | Act: 34 | File No.: 001-40353 | Film No.: 231187408
SIC: 2834 Pharmaceutical Preparations